Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes



Status:Archived
Conditions:Breast Cancer, Skin Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:June 2010
End Date:May 2011

Use our guide to learn which trials are right for you!

A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping


Data from this pivotal clinical trial will be used to support a marketing application (i.e.,
NDA) of Neoprobe's Lymphoseek for use in anatomical delineation of lymphoid tissue (nodes)
in the lymphatic pathway draining the primary site of a tumor.

Multicenter, open-label, within-patient comparative study of Lymphoseek and vital blue dye
in the detection of excised lymph nodes in patients with known melanoma and breast cancer.
All patients will receive a single dose of 50 µg Lymphoseek radiolabeled with 0.5 or 1.0 mCi
Tc 99m and vital blue dye.


In patients with primary melanoma and breast cancer, lymph node status is often a strong
predictor of outcome and influences the course of treatment a patient may follow after
surgery. In an effort to reduce the morbidity and costs of detection of lymph node
metastases, surgical oncologists have developed a method by which the sentinel lymph node
(SLN; the first node in a draining basin) is identified intraoperatively and removed. This
technique, called sentinel node biopsy, has extremely high negative predictive values for
melanoma [1] metastases and breast cancer [2] metastases. The two largest trials for
melanoma, Morton, et al (2005) [3] and Rossi, et al (2006) [4], reported false negative
rates of 6.3% and 14.7%, respectively. Morton, et al (2006) [1], in perhaps the most mature
trial reported to date, showed a false negative rate of 3.4%. There is growing evidence that
sentinel node biopsy will have a significant impact on the management of melanoma. Sentinel
node biopsy also has extremely high negative predictive values for breast cancer metastases
[2]; the false-negative rates range from 0% to 9% [5-8]. There is growing evidence that
sentinel node biopsy will have a significant impact on the management of breast cancer
[5,9-11]. Although the survival and local recurrence studies have yet to be completed, the
technique has emerged into common practice.

Intraoperative lymphatic mapping (ILM) with a radiopharmaceutical is a nuclear medicine
examination which identifies for the surgeon the first lymph node to receive lymphatic flow
from the primary tumor site. This node is removed and analyzed for the presence of malignant
cells. By locating the lymph node prior to surgery, a small incision can be used to remove
the node and a smaller dissection can be employed. The high negative predictive value of the
technique seems to provide an accurate staging procedure and may spare patients who are
lymph node negative the morbidity of a complete lymph node dissection [1,2]. Consequently,
staging of melanoma by lymph node mapping and biopsy may be equivalent to regional node
dissection without the attendant post surgical morbidity.

An ideal lymph node imaging agent would exhibit rapid clearance from the injection site,
rapid uptake and high retention within the first draining lymph node, and low uptake by the
remaining lymph nodes. The ideal agent would also have low radiation absorption; high
biological safety; convenient, rapid, and stable technetium-99m labeling; and biochemical
purity.

Lymphoseek (Technetium Tc 99m diethylenetriaminepentaacetic acid mannosyl dextran, [Tc 99m]
DTPA Mannosyl Dextran) is a radiotracer that accumulates in lymphatic tissue by binding to a
mannose binding protein that resides on the surface of dendritic cells and macrophages.
Lymphoseek is a macromolecule consisting of multiple units of DTPA and mannose, each
synthetically attached to a 10 kilodalton dextran backbone. The mannose acts as a substrate
for the receptor, and the DTPA serves as a chelating agent for labeling with Tc 99m.

Lymphoseek has a diameter of about 5 nm, which is substantially smaller than current agents
used for targeting lymphoid tissue. Lymphoseek's small diameter permits enhanced diffusion
into lymph nodes and blood capillaries, resulting in a rapid injection site clearance. Upon
entry into the blood, the agent binds to receptors in the liver or is filtered by the kidney
and accumulates in the urinary bladder


We found this trial at
8
sites
281 W. Lane Ave
Columbus, Ohio 43210
(614) 292-6446
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
2200 Santa Monica Blvd
Santa Monica, California 90404
(310) 582-7438
?
mi
from
Santa Monica, CA
Click here to add this to my saved trials
12902 USF Magnolia Dr
Tampa, Florida 33612
(888) 663-3488
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Birmingham, Alabama 35294
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
10900 Euclid Ave
Cleveland, Ohio 44106
216-368-2000
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Columbus, Ohio 43081
?
mi
from
Columbus, OH
Click here to add this to my saved trials
La Jolla, California 92093
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
45 Castro Street
San Francisco, California 94114
(415) 600-6000
California Pacific Medical Center California Pacific Medical Center is one of the largest private, not-for-profit,...
?
mi
from
San Francisco, CA
Click here to add this to my saved trials